Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06925581 | A Trial of HRS-6768 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 84 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07021898 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.(BOREALIS-1) | recruiting | Phase 1 | 200 | Erasca, Inc.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | recruiting | Phase 1 | 6 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06840821 | Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors | recruiting | Phase 1 / Phase 2 | 156 | Mainline Biosciences (Shanghai) Co., LtdOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259889 | Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors | recruiting | Phase 1 | 13 | Guangzhou Xiling Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 48 | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY | 0 | Dec 2, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07208136 | A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors | recruiting | Phase 1 | 102 | JemincareINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256782 | A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT06220318 | Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 155 | Fujian Haixi Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07241936 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT06215846 | A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors | enrolling by invitation | Phase 1 | 12 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07105215 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | completed | Phase 1 | 60 | Tesaro, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05547321 | Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Oncomatryx Biopharma S.L.INDUSTRY | 2 | Nov 25, 2025 | clinicaltrials |
| NCT06478251 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | TingBo LiangOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06484790 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | Ting DengOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07083323 | A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 262 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07249892 | A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases | not yet recruiting | Phase 1 / Phase 2 | 195 | Chengdu Syncor Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors(MICA) | active not recruiting | Phase 1 | 440 | Cullinan Therapeutics Inc.INDUSTRY | 4 | Nov 24, 2025 | clinicaltrials |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | completed | Phase 1 | 26 | GenmabINDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT05631899 | CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06238401 | An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 77 | Hangzhou Adcoris Biopharmacy Co., LtdINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07232420 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07245901 | Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 862 | DualityBio Inc.INDUSTRY | 4 | Nov 21, 2025 | clinicaltrials |
| NCT06001580 | A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors | completed | Phase 1 | 15 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06232408 | LIONS (PLK4 Inhibitor in Advanced Solid Tumors) | terminated | Phase 1 | 29 | Repare TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06289894 | A Study of BRY805 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 13 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04299191 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 28 | Laminar PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05522868 | SB17170 Phase 1 Clinical Trial in Solid Tumors | recruiting | Phase 1 | 50 | SPARK BiopharmaINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06184035 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer(Tumorad) | recruiting | Phase 1 / Phase 2 | 90 | Spago Nanomedical ABINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06345482 | A Study of MHB039A for Advanced Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 196 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06500676 | A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 407 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05938296 | oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection | suspended | Phase 1 | 29 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06373406 | A Study of MHB036C for Advanced Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07123415 | A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Aptabio Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04999384 | First in Human, Dose Escalation Study of AN4005 | recruiting | Phase 1 | 31 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Nov 18, 2025 | clinicaltrials |
| NCT07126665 | A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 116 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06143007 | A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 42 | Broadenbio Ltd., Co.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06258408 | A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 78 | Broadenbio Ltd., Co.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06618651 | A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 162 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07229898 | A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 48 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07231081 | Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 85 | Tcelltech Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | terminated | Phase 1 | 154 | Novartis PharmaceuticalsINDUSTRY | 9 | Nov 14, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 3, 2025source: clinicaltrials